Histology
Non-Cutaneous Melanoma
CI-CAN-00001283Explore in graph →
87 active trials1 approved drugs22 evidence items
- NCIt
- C8711
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001283Explore in graph →
Clinical trials
312 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (45)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04960891 | A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp(Non Applicable) | available | — | — | Immunocore LtdINDUSTRY | 0 | Jan 21, 2022 | clinicaltrials |
| NCT05179174 | The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma | unknown | — | 102 | University of CataniaOTHER | 2 | Jan 5, 2022 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT02129075 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05047276 | Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma(PULSE-UM) | unknown | Phase 1 / Phase 2 | 16 | José María Piulats RodríguezOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT05009446 | Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM(SNMM) | unknown | Early Phase 1 | 28 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT00324727 | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma | completed | Phase 3 | 93 | Delcath Systems Inc.INDUSTRY | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02913417 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | unknown | Phase 1 / Phase 2 | 26 | David Minor, MDOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT00344799 | Cytogenetic Study of Ocular Melanoma | completed | — | 95 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT01430416 | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | completed | Phase 1 | 153 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT04622566 | Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma | not yet recruiting | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04577742 | Uveal Melanoma and Brachytheraphy: Long-term Outcomes. | completed | — | 350 | Federico II UniversityOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT02771340 | Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma | completed | Phase 1 | 10 | Iconic Therapeutics, Inc.INDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT02363283 | Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02336763 | Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases | terminated | N/A | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT04472806 | Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma(MTAM) | unknown | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04184518 | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma(CEDUVEAL-M) | withdrawn | Phase 2 | 0 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT01413191 | Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2020 | clinicaltrials |
| NCT03022565 | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | withdrawn | Early Phase 1 | 0 | University of MiamiOTHER | 0 | Feb 6, 2020 | clinicaltrials |
| NCT02158520 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 24 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT03941795 | Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma(BJCH-MM-0624) | unknown | Phase 2 | 99 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT01551459 | A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma(SUAVE) | completed | Phase 2 | 124 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT02359851 | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | terminated | Phase 2 | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01471054 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | terminated | Phase 2 | 6 | Arman MashayekhiOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00346372 | Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy | terminated | — | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 12, 2019 | clinicaltrials |
| NCT03602547 | Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. | unknown | Phase 2 | 40 | AnewPharmaINDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03986515 | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 14, 2019 | clinicaltrials |
| NCT02909517 | The Role of Inflammation in Ocular Tumours | unknown | — | 30 | Unity Health TorontoOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT01100528 | Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance | completed | Phase 2 | 38 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00121225 | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 2 | Jan 29, 2019 | clinicaltrials |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | terminated | Phase 1 / Phase 2 | 23 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT00788775 | Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT01200238 | STA-9090(Ganetespib) in Metastatic Ocular Melanoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00243061 | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00450255 | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | May 24, 2018 | clinicaltrials |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT01893099 | Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma | completed | Phase 1 | 11 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT03138642 | Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 12, 2017 | clinicaltrials |
| NCT01034787 | Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma | completed | Phase 2 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01252251 | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 1, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jan 21, 2022source: clinicaltrials